Search

Highlights of Past EHA (HOPE ) Asia 2021 - report

In the first weekend of September (September 3-4), EHA opened the virtual platform for HOPE Asia 2021.

Read more

Meet Shai Izraeli, our volunteer of the month

Can you tell us what you do for EHA and when you started?
I am currently the EHA Treasurer, a member of the Executive Board, and the incoming Chair of the Research Committee.

Read more

Meet Shai Izraeli, our volunteer of the month

Can you tell us what you do for EHA and when you started?
I am currently the EHA Treasurer, a member of the Executive Board, and the incoming Chair of the Research Committee.

Read more

EU health policy: limited scope, high ambition

Over the past decades, the European Union (EU) has become more involved in public health policy. A recent study showed that a majority of policymakers even identifies EU health policy as a priority for 2020-20241.

Read more

Regulation on Health Technology Assessment

The Regulation on Health Technology Assessment (HTAR) was proposed by the European Commission in 2018. It was formally adopted in December 2021 and will apply from January 2025.

Read more

EHA-KCS Hematology Tutorial on Lymphoma and Multiple Myeloma

Dates: March 14-16, 2019
Location: Almaty, Kazakhstan
Chairs: G Gaidano, D Kaidarova
Co-chairs: S Gabbasova, B Afanasyev 

This meeting will be held in English and offer a simultaneous translation to Russian.

Read more

The root of evil: pre-leukemic clones that survive chemotherapy are linked to a higher risk of leukemia recurrence

Acute myeloid leukemia (AML) is an aggressive form of blood cancer. Treatment with intensive chemotherapy often leads to a period of freedom from overt disease called a remission. However, recurrence of the disease is common.

Read more

SGN-CD33A Combined with Hypomethylating Therapy Produces High Remission Rates among Older Patients with AML

Acute myeloid leukemia (AML) is an aggressive form of blood cancer in which the majority of cases express CD33 on the surface of the leukemia cells.

Read more